255 related articles for article (PubMed ID: 24307346)
1. Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Med Oncol; 2014 Jan; 31(1):792. PubMed ID: 24307346
[TBL] [Abstract][Full Text] [Related]
2. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
4. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
[TBL] [Abstract][Full Text] [Related]
5. UNC-51-like kinase 1 expression in radical nephrectomy specimens as a predicting factor of progression-free survival in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors.
Nishikawa M; Miyake H; Bing L; Fujisawa M
Urol Oncol; 2015 Dec; 33(12):506.e1-7. PubMed ID: 26299883
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
[TBL] [Abstract][Full Text] [Related]
7. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
Nawroth R; Stellwagen F; Schulz WA; Stoehr R; Hartmann A; Krause BJ; Gschwend JE; Retz M
PLoS One; 2011; 6(11):e27509. PubMed ID: 22110663
[TBL] [Abstract][Full Text] [Related]
8. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
[TBL] [Abstract][Full Text] [Related]
9. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.
Liontos M; Trigka EA; Korkolopoulou P; Tzannis K; Lainakis G; Koutsoukos K; Kostouros E; Lykka M; Papandreou CN; Karavasilis V; Christodoulou C; Papatsoris A; Skolarikos A; Varkarakis I; Adamakis I; Alamanis C; Stravodimos K; Mitropoulos D; Deliveliotis C; Constantinidis CA; Saetta A; Patsouris E; Dimopoulos MΑ; Bamias A
World J Urol; 2017 Mar; 35(3):411-419. PubMed ID: 27395374
[TBL] [Abstract][Full Text] [Related]
11. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
13. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
[TBL] [Abstract][Full Text] [Related]
14. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Terakawa T; Miyake H; Kusuda Y; Fujisawa M
Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous activation of impaired autophagy and the mammalian target of rapamycin pathway in oral squamous cell carcinoma.
Yin X; Hu L; Feng X; Wang H; Zhang C; Wang H; Wang S
J Oral Pathol Med; 2019 Sep; 48(8):705-711. PubMed ID: 31132188
[TBL] [Abstract][Full Text] [Related]
16. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
[TBL] [Abstract][Full Text] [Related]
17. Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma.
Chuang CK; Lin HCA; Tasi HY; Lee KH; Kao Y; Chuang FL; Chang YH; Lin PH; Liu CY; Pang ST
Int Urol Nephrol; 2017 Sep; 49(9):1527-1536. PubMed ID: 28547571
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
[TBL] [Abstract][Full Text] [Related]
19. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma.
Li SH; Chen CH; Lu HI; Huang WT; Tien WY; Lan YC; Lee CC; Chen YH; Huang HY; Chang AY; Lin WC
Surgery; 2015 Mar; 157(3):570-80. PubMed ID: 25726316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
